Suppr超能文献

鲁氏不动杆菌和鲍曼不动杆菌临床分离株产生的染色体头孢菌素酶的特性分析

Characterization of the chromosomal cephalosporinases produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates.

作者信息

Perilli M, Felici A, Oratore A, Cornaglia G, Bonfiglio G, Rossolini G M, Amicosante G

机构信息

Dipartimento di Scienze e Tecnologie Biomediche e di Biometria, Università degli Studi dell'Aquila, Italy.

出版信息

Antimicrob Agents Chemother. 1996 Mar;40(3):715-9. doi: 10.1128/AAC.40.3.715.

Abstract

The beta-lactamases produced by Acinetobacter lwoffii ULA-501, Acinetobacter baumannii ULA-187, and A. baumannii AC-14 strains were purified and characterized, and their kinetic interactions with several beta-lactam molecules, including substrates and inhibitors, were studied in detail. The three enzymes appeared to be cephalosporinases with different acylation efficiencies (kcat/Km ratio values), and their hydrolytic activities were inhibited by benzylpenicillin, piperacillin, and cefotaxime, which did not behave as substrates. Carbenicillin was a substrate for the beta-lactamase from A. lwoffii ULA-501, whereas it acted as a transient inactivator of the enzymes produced by the two A. baumannii strains. Clavulanic acid was unable to inactivate the three beta-lactamases, whereas sulbactam behaved as an inactivator only at a high concentration (1 mM) which is difficult to achieve during antibiotic therapy. Analysis of the interaction with 6-beta-iodopenicillanic acid also allowed us to better discriminate the three beta-lactamases analyzed in the present study, which can be included in the group 1 functional class (5).

摘要

对沃氏不动杆菌ULA - 501、鲍曼不动杆菌ULA - 187和鲍曼不动杆菌AC - 14菌株产生的β-内酰胺酶进行了纯化和表征,并详细研究了它们与几种β-内酰胺分子(包括底物和抑制剂)的动力学相互作用。这三种酶似乎是具有不同酰化效率(kcat/Km比值)的头孢菌素酶,它们的水解活性受到苄青霉素、哌拉西林和头孢噻肟的抑制,而这些药物并不作为底物。羧苄青霉素是沃氏不动杆菌ULA - 501产生的β-内酰胺酶的底物,而它对两种鲍曼不动杆菌菌株产生的酶起到瞬时灭活作用。克拉维酸无法使这三种β-内酰胺酶失活,而舒巴坦仅在高浓度(1 mM)时才表现出灭活作用,而这一浓度在抗生素治疗期间很难达到。对与6-β-碘青霉烷酸相互作用的分析也使我们能够更好地区分本研究中分析的三种β-内酰胺酶,它们可归入第1功能类(5)。

相似文献

2
5
In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species.
Diagn Microbiol Infect Dis. 1995 Feb;21(2):111-4. doi: 10.1016/0732-8893(95)00020-b.
10
Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter.
Future Microbiol. 2011 May;6(5):495-511. doi: 10.2217/fmb.11.30.

引用本文的文献

1
Molecular and Kinetic Characterization of MOX-9, a Plasmid-Mediated Enzyme Representative of a Novel Sublineage of MOX-Type Class C β-Lactamases.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0059522. doi: 10.1128/aac.00595-22. Epub 2022 Aug 30.
3
OmpA is the principal nonspecific slow porin of Acinetobacter baumannii.
J Bacteriol. 2012 Aug;194(15):4089-96. doi: 10.1128/JB.00435-12. Epub 2012 May 25.
4
Interaction of Acinetobacter baumannii 19606 and 1656-2 with Acanthamoeba castellanii.
J Microbiol. 2011 Oct;49(5):841-6. doi: 10.1007/s12275-011-1063-8. Epub 2011 Nov 9.
5
Multidrug resistant acinetobacter.
J Glob Infect Dis. 2010 Sep;2(3):291-304. doi: 10.4103/0974-777X.68538.
6
Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2010 Nov;54(11):4678-83. doi: 10.1128/AAC.00497-10. Epub 2010 Aug 16.
7
Acinetobacter baumannii: emergence of a successful pathogen.
Clin Microbiol Rev. 2008 Jul;21(3):538-82. doi: 10.1128/CMR.00058-07.

本文引用的文献

1
Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore.
Antimicrob Agents Chemother. 1994 Oct;38(10):2502-3. doi: 10.1128/AAC.38.10.2502.
3
A functional classification scheme for beta-lactamases and its correlation with molecular structure.
Antimicrob Agents Chemother. 1995 Jun;39(6):1211-33. doi: 10.1128/AAC.39.6.1211.
4
Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria.
Antimicrob Agents Chemother. 1982 Sep;22(3):414-20. doi: 10.1128/AAC.22.3.414.
6
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature. 1970 Aug 15;227(5259):680-5. doi: 10.1038/227680a0.
7
An underestimated nosocomial pathogen, Acinetobacter calcoaceticus.
J Antimicrob Chemother. 1985 Nov;16(5):535-8. doi: 10.1093/jac/16.5.535.
8
Enzymatic resistance to beta-lactams and aminoglycosides in Acinetobacter calcoaceticus.
J Antimicrob Chemother. 1987 Dec;20(6):773-6. doi: 10.1093/jac/20.6.773.
9
Distribution of beta-lactamases and phenotype analysis in clinical strains of Acinetobacter calcoaceticus.
J Antimicrob Chemother. 1988 Nov;22(5):597-604. doi: 10.1093/jac/22.5.597.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验